PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Both yoy net incomes decline, with AGEN at -138.14%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.01%
Some D&A expansion while AGEN is negative at -1.55%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
9.00%
SBC growth well above AGEN's 8.52%. Michael Burry would flag major dilution risk vs. competitor’s approach.
715.46%
Well above AGEN's 184.37% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
AP growth well above AGEN's 98.70%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
304.81%
Growth well above AGEN's 127.00%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
412.12%
Some yoy increase while AGEN is negative at -129.60%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
9.59%
Some CFO growth while AGEN is negative at -117.45%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth well above AGEN's 59.97%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above AGEN's 51.44%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-4.76%
Both yoy lines negative, with AGEN at -16.67%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
-85.80%
Both yoy lines negative, with AGEN at -5.46%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.